KR101215801B1 - 항?ＮｏｇｏＡ 항체 (″１Ｃ７″) 및 그의 제약상 용도 - Google Patents

항?ＮｏｇｏＡ 항체 (″１Ｃ７″) 및 그의 제약상 용도 Download PDF

Info

Publication number
KR101215801B1
KR101215801B1 KR1020057010410A KR20057010410A KR101215801B1 KR 101215801 B1 KR101215801 B1 KR 101215801B1 KR 1020057010410 A KR1020057010410 A KR 1020057010410A KR 20057010410 A KR20057010410 A KR 20057010410A KR 101215801 B1 KR101215801 B1 KR 101215801B1
Authority
KR
South Korea
Prior art keywords
ser
glu
leu
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057010410A
Other languages
English (en)
Korean (ko)
Other versions
KR20050095768A (ko
Inventor
카르멘 바르스케
아니스 쿠스로 미르
토마스 외르틀
리자 쉬넬
마르틴 에. 쉬밥
알레싼드라 비탈리티
마우로 쥬리니
Original Assignee
유니베르시태트 취리히
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니베르시태트 취리히, 노파르티스 아게 filed Critical 유니베르시태트 취리히
Publication of KR20050095768A publication Critical patent/KR20050095768A/ko
Application granted granted Critical
Publication of KR101215801B1 publication Critical patent/KR101215801B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020057010410A 2002-12-10 2003-12-09 항?ＮｏｇｏＡ 항체 (″１Ｃ７″) 및 그의 제약상 용도 Expired - Fee Related KR101215801B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0228832.2 2002-12-10
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound

Publications (2)

Publication Number Publication Date
KR20050095768A KR20050095768A (ko) 2005-09-30
KR101215801B1 true KR101215801B1 (ko) 2012-12-26

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057010410A Expired - Fee Related KR101215801B1 (ko) 2002-12-10 2003-12-09 항?ＮｏｇｏＡ 항체 (″１Ｃ７″) 및 그의 제약상 용도

Country Status (24)

Country Link
US (2) US7785593B2 (https=)
EP (1) EP1572745B1 (https=)
JP (1) JP4504200B2 (https=)
KR (1) KR101215801B1 (https=)
CN (1) CN100384877C (https=)
AT (1) ATE475671T1 (https=)
AU (1) AU2003289998B2 (https=)
BR (1) BR0317161A (https=)
CA (1) CA2509068C (https=)
CY (1) CY1110848T1 (https=)
DE (1) DE60333585D1 (https=)
DK (1) DK1572745T3 (https=)
EC (1) ECSP055849A (https=)
ES (1) ES2349293T3 (https=)
GB (1) GB0228832D0 (https=)
IL (1) IL169018A (https=)
MX (1) MXPA05006265A (https=)
NO (1) NO20053304L (https=)
PL (1) PL210720B1 (https=)
PT (1) PT1572745E (https=)
RU (1) RU2350623C2 (https=)
SI (1) SI1572745T1 (https=)
WO (1) WO2004052932A2 (https=)
ZA (1) ZA200504522B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
KR20080030960A (ko) * 2005-07-05 2008-04-07 글락소 그룹 리미티드 Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
HRP20130699T1 (hr) 2007-11-02 2013-11-22 Novartis Ag Poboljšane molekule koje se vežu na nogo-a i njihova farmaceutska uporaba
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CN105491883B (zh) * 2013-06-13 2018-11-02 生物马特里卡公司 细胞稳定化
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
WO2021070181A1 (en) 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2021079002A2 (en) * 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
IL150566A0 (en) 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
EP1461300B1 (en) * 2001-11-30 2011-07-27 Biogen Idec MA Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
CA2549956C (en) 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Protein Engineering Vol.15, pp.931-941(2002.11.).*

Also Published As

Publication number Publication date
ES2349293T3 (es) 2010-12-29
JP4504200B2 (ja) 2010-07-14
BR0317161A (pt) 2005-11-01
GB0228832D0 (en) 2003-01-15
AU2003289998B2 (en) 2008-02-14
PL377506A1 (pl) 2006-02-06
US8535666B2 (en) 2013-09-17
PT1572745E (pt) 2010-10-21
JP2006523087A (ja) 2006-10-12
CA2509068C (en) 2012-02-07
PL210720B1 (pl) 2012-02-29
US7785593B2 (en) 2010-08-31
RU2350623C2 (ru) 2009-03-27
CN1747971A (zh) 2006-03-15
WO2004052932A2 (en) 2004-06-24
DE60333585D1 (de) 2010-09-09
CN100384877C (zh) 2008-04-30
IL169018A (en) 2012-07-31
CY1110848T1 (el) 2015-06-10
EP1572745B1 (en) 2010-07-28
NO20053304L (no) 2005-09-07
RU2005121669A (ru) 2007-01-20
ECSP055849A (es) 2005-09-20
EP1572745A2 (en) 2005-09-14
MXPA05006265A (es) 2005-12-05
KR20050095768A (ko) 2005-09-30
SI1572745T1 (sl) 2010-12-31
DK1572745T3 (da) 2010-10-25
NO20053304D0 (no) 2005-07-06
CA2509068A1 (en) 2004-06-24
ZA200504522B (en) 2006-03-29
WO2004052932A3 (en) 2004-10-21
US20060183678A1 (en) 2006-08-17
HK1084676A1 (en) 2006-08-04
AU2003289998A1 (en) 2004-06-30
ATE475671T1 (de) 2010-08-15
US20110059110A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
US8535666B2 (en) Antibody (11C7) anti Nogo-A and its pharmaceutical use
EP2084190B1 (en) Lingo binding molecules and pharmaceutical use thereof
AU2017384681A1 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
AU2009200237B2 (en) NOGO-A Binding Molecule and Pharmaceutical Use Thereof
TWI429656B (zh) 改良之ｎｏｇｏ－ａ結合分子及其醫藥用途
US20240270866A1 (en) Anti-SIRP-Alpha Antibodies and Methods of Use Thereof
HK1084676B (en) Antibody anti human nogo a and its pharmaceutical use
NZ554011A (en) Antibody ("11C7") anti nogo A and its pharmaceutical use
MXPA06003057A (en) Nogo-a binding with enhanced affinity and pharmaceutical use thereof
HK1163713A (en) Nogo-a binding molecules and pharmaceutical use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151219

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151219

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000